Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and care of patients with cancer owing to unique features, including the occurrence of the so-called immune-related adverse events (irAEs). A multidisciplinary team, possibly including a cardio-oncology specialist, is warranted to achieve a favorable patient outcome. Cardiovascular toxicity, especially myocarditis, emerged as a life-threatening irAE in the real-word setting, and the European Society of Cardiology has recently published the first guideline on cardio-oncology to increase awareness and promote a standardized approach to tackle this complex multimodal issue, including diagnostic challenges, assessment, treatment, and surveillance of patients with cancer receiving ICIs. In this article, through a question & a

SUBMITTER: Raschi E 

PROVIDER: S-EPMC10442274 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature